Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMUICJD)

Drug Name
SAR-156597 Drug Info
Synonyms IL-4/IL-13-targeting bispecific mAb (idiopathic pulmonary fibrosis), sanofi-aventis
Indication
Disease Entry ICD 11 Status REF
Idiopathic pulmonary fibrosis CB03.4 Phase 2 [1]
Pulmonary fibrosis CB03.4 Phase 2 [2]
Systemic sclerosis 4A42 Phase 2 [3]
Cross-matching ID
TTD Drug ID
DMUICJD

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin 4 receptor alpha (IL4R) TTDWHC3 IL4RA_HUMAN Not Available [4]
Interleukin-13 (IL13) TT0GVCH IL13_HUMAN Modulator [5]
Interleukin-4 (IL4) TTLGTKB IL4_HUMAN Modulator [5]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Interleukin 4 receptor alpha (IL4R) DTT IL4R 8.599 8.06 6.589 7.357
Interleukin-13 (IL13) DTT IL13 3.036 2.945 1.848 3.776
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Idiopathic pulmonary fibrosis
ICD Disease Classification CB03.4
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin 4 receptor alpha (IL4R) DTT IL4R 1.48E-08 0.76 3.74
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT02345070) Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis
2 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034106)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1697).
5 Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.